Notice: Global Information Announces Listing on JASDAQ Standard Market of the Tokyo Stock Exchange

Cover Image
Market Research Report

Global HIV Drugs Market By Medication Class : Opportunity Analysis and Industry Forecast, 2020-2027

Published by Allied Market Research Product code 980719
Published Content info 237 Pages
Delivery time: 2-3 business days
Price
Back to Top
Global HIV Drugs Market By Medication Class : Opportunity Analysis and Industry Forecast, 2020-2027
Published: November 20, 2020 Content info: 237 Pages
Description

Title:
Global HIV Drugs Market By Medication Class (Multi-class Combination Drugs, Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Entry Inhibitors, and HIV Integrase Strand Transfer Inhibitors): Opportunity Analysis and Industry Forecast, 2020-2027.

The global HIV drugs market was valued at $30,891.48 million in 2019, and is expected to reach $36,495.47 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Human immunodeficiency virus (HIV) attacks the body's immune system, leading to complete damage of the system and making the host system susceptible to infection. The virus attacks the CD4 cells, whose primary role is to help the immune system defend infections, thus destroying the first line of defense of the human body and exposing the person to various infections. HIV is one of the most alarming and widespread diseases globally. The major route of transmission of HIV infection is through unprotected sex, use of contaminated needles, breast milk of HIV-infected mother to child, and infected blood.

The global HIV drugs market is bifurcated into medication class and region. On the basis of medication class, the market is classified into multi-class combination drugs, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), entry inhibitors, and HIV integrase strand transfer inhibitors. In the medication class, the multi-class combination drugs segment holds the largest market share as it involves the most advanced technique used for the treatment of HIV infection. Furthermore, this is attributed to the increase in adoption of drugs from this medication class, owing to their better results in the control of HIV & related co-infections and their ease in consumption & adherence.

Based on region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA. North America accounted for the largest market share in 2015, owing to increase in the number of HIV-infected individuals, advancement in HIV treatment, and rise in government funding for R&D for drug manufacturing. In addition, Asia-Pacific is expected to emerge with the maximum growth potential due to the focus of key players on emerging economies, mainly on the health of people with effective treatment for different diseases and rise in incidence of HIV infection.

The report provides a comprehensive analysis of key players that operate in the HIV drugs market such as Boehringer Ingelheim International GmbH, Merck & Co., Inc., Pfizer Inc., Gilead Sciences, Inc., GalaxoSmithKline plc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., AbbVie, and Cipla.

KEY BENEFITS FOR STAKEHOLDERS

The study provides in-depth analysis of the market along with the current trends and future estimations to explain the imminent investment pockets.

The report offers a quantitative analysis from 2019 to 2027, which is expected to enable stakeholders to capitalize on the prevailing market opportunities.

The key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Medication Class

  • Multi-class Combination Drugs
  • Atripla
  • Complera
  • Prezcobix/Prezista
  • Stribild
  • Genvoya
  • Odefsey
  • Symtuza
  • Triumeq
  • Descovy
  • Others
  • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
  • Emtriva
  • Epivir
  • Epzicom
  • Truvada
  • Biktarvy
  • Others
  • Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
  • Edurant
  • Others
  • Protease Inhibitors(PIs)
  • Aptivus
  • Kaletra
  • Lexiva
  • Norvir
  • Viracept
  • Others
  • Entry Inhibitors
  • Selzentry
  • HIV Integrase Strand Transfer Inhibitors
  • Isentress
  • Tivicay

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • List of key players profiled in the report
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Gilead Sciences, Inc.
  • GalaxoSmithKline plc. (ViiV Healthcare)
  • Johnson & Johnson
  • F. Hoffmann-La Roche Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • AbbVie
  • Cipla
Table of Contents
Product Code: A01537

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
    • 1.2.1.List of key players profiled in the report
  • 1.3.Research methodology
    • 1.3.1.Primary research
    • 1.3.2.Secondary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
    • 3.1.1.Top winning strategies, 2019
  • 3.2.Top player positioning
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Market dynamics
    • 3.4.1.Drivers
      • 3.4.1.1.Increase in number of HIV infected patients worldwide
      • 3.4.1.2.Initiatives taken by various government associations to raise awareness about diagnosis and management of HIV/AIDS
      • 3.4.1.3.Introduction of generic drugs of HIV drugs
    • 3.4.2.Restraint
      • 3.4.2.1.Stringent regulatory requirements for the approval and commercialization of HIV drugs
    • 3.4.3.Opportunity
      • 3.4.3.1.Increasing number of products in the pipeline
    • 3.4.4.Impact Analysis
  • 3.1.COVID-19 impact on the HIV Drugs market

CHAPTER 4:HIV DRUGS MARKET, BY MEDICATION CLASS

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.MULTICLASS COMBINATION DRUGS
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
    • 4.2.4.Multiclass combination drugs, By brand
      • 4.2.4.1.Market size and forecast
      • 4.2.4.2.Atripla, market size and forecast
      • 4.2.4.3.Complera, market size and forecast
      • 4.2.4.4.Prezcobix/prezista, market size and forecast
      • 4.2.4.5.Stribild, market size and forecast
      • 4.2.4.6.Genvoya, market size and forecast
      • 4.2.4.7.Odefsey, market size and forecast
      • 4.2.4.8.Symtuza, market size and forecast
      • 4.2.4.9.Trimeq, market size and forecast
      • 4.2.4.10.Descovy, market size and forecast
      • 4.2.4.11.Others, market size and forecast
  • 4.3.NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
    • 4.3.4.Nucleoside reverse transcriptase inhibitors (NRTIs), By brand
      • 4.3.4.1.Market size and forecast
      • 4.3.4.2.Emtriva, market size and forecast
      • 4.3.4.3.Epivir, market size and forecast
      • 4.3.4.4.Epzicom, market size and forecast
      • 4.3.4.5.Truvada, market size and forecast
      • 4.3.4.6.Biktavry, market size and forecast
      • 4.3.4.7.Others, market size and forecast
  • 4.4.NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
    • 4.4.4.Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), By brand
      • 4.4.4.1.Market size and forecast
      • 4.4.4.2.Edurant, market size and forecast
      • 4.4.4.3.Others, market size and forecast
  • 4.5.PROTEASE INHIBITORS (PIs)
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
    • 4.5.4.Protease Inhibitors, By brand
      • 4.5.4.1.Market size and forecast
      • 4.5.4.2.Aptivus, market size and forecast
      • 4.5.4.3.Kaletra, market size and forecast
      • 4.5.4.4.Lexiva, market size and forecast
      • 4.5.4.5.Norvir, market size and forecast
      • 4.5.4.6.Viracept, market size and forecast
      • 4.5.4.7.Others, market size and forecast
  • 4.6.ENTRY INHIBITORS - CCR5 co-receptor antagonist
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country
    • 4.6.4.Entry Inhibitors - CCR5 co-receptor antagonist, By brand
      • 4.6.4.1.Selzentry, market size and forecast
  • 4.7.HIV INTEGRASE STRAND TRANSFER INHIBITORS
    • 4.7.1.Key market trends, growth factors, and opportunities
    • 4.7.2.Market size and forecast, by region
    • 4.7.3.Market analysis, by country
    • 4.7.4.HIV integrase strand transfer inhibitors, By brand
      • 4.7.4.1.Market size and forecast
      • 4.7.4.2.Isentress, market size and forecast
      • 4.7.4.3.Tivicay, market size and forecast

CHAPTER 5:HIV DRUGS MARKET, BY REGION

  • 5.1.Overview

Market size and forecast

  • 5.2.North America
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by country
      • 5.2.2.1.U.S. market size and forecast, by medication class
      • 5.2.2.2.Canada market size and forecast, by medication class
      • 5.2.2.3.Mexico market size and forecast, by medication class
    • 5.2.3.North America, market size and forecast, by medication class
  • 5.3.Europe
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast, by country
      • 5.3.2.1.Germany market size and forecast, by medication class
      • 5.3.2.2.France market size and forecast, by medication class
      • 5.3.2.3.UK market size and forecast, by medication class
      • 5.3.2.4.Italy market size and forecast, by medication class
      • 5.3.2.5.Spain market size and forecast, by medication class
      • 5.3.2.6.Rest of Europe market size and forecast, by medication class
    • 5.3.3.Europe, market size and forecast, by medication class
  • 5.4.Asia-Pacific
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast, by country
      • 5.4.2.1.Japan market size and forecast, by medication
      • 5.4.2.2.China market size and forecast, by medication
      • 5.4.2.3.India market size and forecast, by medication
      • 5.4.2.4.Australia market size and forecast, by medication
      • 5.4.2.5.Rest of Asia-Pacific market size and forecast, by medication
    • 5.4.3.Asia-Pacific, market size and forecast, by medication class
  • 5.5.LAMEA
    • 5.5.1.Key market trends, growth factors, and opportunities
    • 5.5.2.Market size and forecast, by country
      • 5.5.2.1.Brazil market size and forecast, by medication class
      • 5.5.2.2.South Africa market size and forecast, by medication class
      • 5.5.2.3.Saudi Arabia market size and forecast, by medication class
      • 5.5.2.4.Rest of LAMEA, market size and forecast, by medication class
    • 5.5.3.LAMEA, market size and forecast, by medication class

CHAPTER 6:COMPANY PROFILES

  • 6.1.AbbVie Inc.
    • 6.1.1.Company overview
    • 6.1.2.Company snapshot
    • 6.1.3.Operating business segments
    • 6.1.4.Product portfolio
    • 6.1.5.Business performance
    • 6.1.6.Key strategic moves and developments
  • 6.2.Boehringer Ingelheim International GmbH
    • 6.2.1.Company overview
    • 6.2.2.Company snapshot
    • 6.2.3.Operating business segments
    • 6.2.4.Product portfolio
    • 6.2.5.Business performance
  • 6.3.Cipla Inc.
    • 6.3.1.Company overview
    • 6.3.2.Company snapshot
    • 6.3.3.Operating business segments
    • 6.3.4.Product portfolio
    • 6.3.5.Business performance
    • 6.3.6.Key strategic moves and developments
  • 6.4.F. Hoffmann-La Roche Ltd.
    • 6.4.1.Company overview
    • 6.4.2.Company snapshot
    • 6.4.3.Operating business segments
    • 6.4.4.Product portfolio
    • 6.4.5.Business performance.
  • 6.5.Gilead Sciences, Inc.
    • 6.5.1.Company overview
    • 6.5.2.Company snapshot
    • 6.5.3.Operating business segments
    • 6.5.4.Product portfolio
    • 6.5.5.Business performance
  • 6.6.GLAXOSMITHKLINE PLC. (ViiV Healthcare)
    • 6.6.1.Company overview
    • 6.6.2.Company snapshot
    • 6.6.3.Operating business segments
    • 6.6.4.Product portfolio
    • 6.6.5.Business performance
    • 6.6.6.Key strategic moves and developments
  • 6.7.Johnson & Johnson
    • 6.7.1.Company overview
    • 6.7.2.Company snapshot
    • 6.7.3.Operating business segments
    • 6.7.4.Product portfolio
    • 6.7.5.Business performance
  • 6.8.MERCK & CO., INC.
    • 6.8.1.Company overview
    • 6.8.2.Company snapshot
    • 6.8.3.Operating business segments
    • 6.8.4.Product portfolio
    • 6.8.5.Business performance
    • 6.8.6.Key strategic moves and developments
  • 6.9.PFIZER INC.
    • 6.9.1.Company snapshot
    • 6.9.2.Operating business segments
    • 6.9.3.Product portfolio
    • 6.9.4.Business performance
  • 6.10.Teva Pharmaceutical Industries Ltd.
    • 6.10.1.Company overview
    • 6.10.2.Company snapshot
    • 6.10.3.Operating business segments
    • 6.10.4.Product portfolio
    • 6.10.5.Business performance
    • 6.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 02.HIV DRUGS MARKET FOR MULTICLASS COMBINATION DRUG, BY REGION, 2019-2027 ($MILLION)
  • TABLE 03.MULTICALSS COMBINATION DRUGS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 04.HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS), BY REGION, 2019-2027 ($MILLION)
  • TABLE 05.NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIS)MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 06.HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 07.NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 08.HIV DRUGS MARKET FOR PROTEASE INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 09.PROTEASE INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 10.HIV DRUGS MARKET FOR ENTRY INHIBITORS - CCR5 CO-RECEPTOR ANTAGONIST, BY REGION, 2019-2027 ($MILLION)
  • TABLE 11.HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2019-2027 ($MILLION)
  • TABLE 12.HIV INTEGRASE STRAND TRANSFER INHIBITORS MARKET, BY BRAND, 2019-2027 ($MILLION)
  • TABLE 13.HIV DRUGS MARKET, BY REGION, 2019-2027 ($MILLION)
  • TABLE 14.NORTH AMERICA HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 15.U.S. HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 16.CANADA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 17.MEXICO HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 18.NORTH AMERICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 19.EUROPE HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 20.GERMANY HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 21.FRANCE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 22.UK HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 23.ITALY HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 24.SPAIN HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 25.REST OF EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 26.EUROPE HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 27.ASIA-PACIFIC HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 28.JAPAN HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 29.CHINA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 30.INDIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 31.AUSTRALIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 32.REST OF ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 33.ASIA-PACIFIC HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 34.LAMEA HIV DRUGS MARKET, BY COUNTRY, 2019-2027 ($MILLION)
  • TABLE 35.BRAZIL HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 36.SOUTH AFRICA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 37.SAUDI ARABIA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 38.REST OF LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 39.LAMEA HIV DRUGS MARKET, BY MEDICATION CLASS, 2019-2027 ($MILLION)
  • TABLE 40.ABBVIE: COMPANY SNAPSHOT
  • TABLE 41.ABBVIE: OPERATING SEGMENTS
  • TABLE 42.ABBVIE: PRODUCT PORTFOLIO
  • TABLE 43.ABBVIE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 44.BOEHRINGER INGELHEIM: COMPANY SNAPSHOT
  • TABLE 45.GSK: OPERATING SEGMENTS
  • TABLE 46.GSK: PRODUCT PORTFOLIO
  • TABLE 47.CIPLA: COMPANY SNAPSHOT
  • TABLE 48.CIPLA: OPERATING SEGMENTS
  • TABLE 49.CIPLA: PRODUCT PORTFOLIO
  • TABLE 50.CIPLA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 51.ROCHE: COMPANY SNAPSHOT
  • TABLE 52.ROCHE: OPERATING SEGMENTS
  • TABLE 53.ROCHE: PRODUCT PORTFOLIO
  • TABLE 54.GILEAD: COMPANY SNAPSHOT
  • TABLE 55.GILEAD: OERATING SEGMENT
  • TABLE 56.GILEAD: PRODUCT PORTFOLIO
  • TABLE 57.GSK: COMPANY SNAPSHOT
  • TABLE 58.GSK: OPERATING SEGMENTS
  • TABLE 59.GSK: PRODUCT PORTFOLIO
  • TABLE 60.GSK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 61.J&J: COMPANY SNAPSHOT
  • TABLE 62.J&J: OPERATING SEGMENTS
  • TABLE 63.J&J: PRODUCT PORTFOLIO
  • TABLE 64.MERCK : COMPANY SNAPSHOT
  • TABLE 65.MERCK : OPERATING SEGMENTS
  • TABLE 66.MERCK: PRODUCT PORTFOLIO
  • TABLE 67.MERCK: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 68.PFIZER: COMPANY SNAPSHOT
  • TABLE 69.PFIZER: OPERATING SEGMENTS
  • TABLE 70.PFIZER: PRODUCT PORTFOLIO
  • TABLE 71.TEVA: COMPANY SNAPSHOT
  • TABLE 72.TEVA: OPERATING SEGMENTS
  • TABLE 73.TEVA: PRODUCT PORTFOLIO
  • TABLE 74.TEVA: KEY STRATEGIC MOVES AND DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 01.GLOBAL HIV DRUGS MARKET SEGMENTATION
  • FIGURE 02.TOP WINNING STRATEGIES, BY DEVELOPMENTS, 2017-2020*
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2017-2020*
  • FIGURE 04.TOP WINNING STRATEGIES: COMPANY , 2017-2020
  • FIGURE 05.TOP PLAYER POSITIONING, 2019
  • FIGURE 06.TOP INVESTMENT POCKETS
  • FIGURE 07.MODERATE BARGAINING POWER OF SUPPLIER
  • FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 10.MODERATE INTENSITY OF RIVALRY
  • FIGURE 11.HIGH THREAT OF NEW ENTRANT
  • FIGURE 12.IMPACT ANALYSES, HIV DRUGS MARKET
  • FIGURE 13.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR MULTI CLASS COMBINATION DRUGS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 14.ATRIPLA MARKET, 2019-2027 ($MILLION)
  • FIGURE 15.COMPLERA MARKET, 2019-2027 ($MILLION)
  • FIGURE 16.PREZCOBIX/PREZISTA MARKET, 2019-2027 ($MILLION)
  • FIGURE 17.STRIBILD MARKET, 2019-2027 ($MILLION)
  • FIGURE 18.GENVOYA MARKET, 2019-2027 ($MILLION)
  • FIGURE 19.ODEFSEY MARKET, 2019-2027 ($MILLION)
  • FIGURE 20.SYMTUZA MARKET, 2019-2027 ($MILLION)
  • FIGURE 21.TRIMEQ MARKET, 2019-2027 ($MILLION)
  • FIGURE 22.DESCOVY MARKET, 2019-2027 ($MILLION)
  • FIGURE 23.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 24.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 25.EMTRIVA MARKET, 2019-2027 ($MILLION)
  • FIGURE 26.EPIVIR MARKET, 2019-2027 ($MILLION)
  • FIGURE 27.EPZICOM MARKET, 2019-2027 ($MILLION)
  • FIGURE 28.TRUVADA MARKET, 2019-2027 ($MILLION)
  • FIGURE 29.BIKTAVRY MARKET, 2019-2027 ($MILLION)
  • FIGURE 30.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 31.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 32.EDURANT MARKET, 2019-2027 ($MILLION)
  • FIGURE 33.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 34.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 35.APTIVUS MARKET, 2019-2027 ($MILLION)
  • FIGURE 36.KALETRA MARKET, 2019-2027 ($MILLION)
  • FIGURE 37.LEXIVA MARKET, 2019-2027 ($MILLION)
  • FIGURE 38.NORVIR MARKET, 2019-2027 ($MILLION)
  • FIGURE 39.VIRACEPT MARKET, 2019-2027 ($MILLION)
  • FIGURE 40.OTHERS MARKET, 2019-2027 ($MILLION)
  • FIGURE 41.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR ENTRY INHIBITORS CCR5 CO RECEPTOR ANTAGONIST, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 42.SELZENTRY MARKET, 2019-2027 ($MILLION)
  • FIGURE 43.COMPARATIVE ANALYSIS OF HIV DRUGS MARKET FOR HIV INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2019 & 2027 (%)
  • FIGURE 44.ISENTRESS MARKET, 2019-2027 ($MILLION)
  • FIGURE 45.TIVICAY MARKET, 2019-2027 ($MILLION)
  • FIGURE 46.ABBVIE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 47.ABBVIE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 48.ABBVIE: REVENUE SHARE BY REGION, 2019(%)
  • FIGURE 49.BOEHRINGER INGELHEIM: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 50.BOEHRINGER INGELHEIM: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 51.BOEHRINGER INGELHEIM: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 52.CIPLA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 53.CIPLA: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 54.CIPLA: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 55.ROCHE: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 56.ROCHE: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 57.ROCHE: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 58.GILEAD: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 59.GSK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 60.GSK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 61.GSK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 62.J&J: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 63.J&J: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 64.J&J: REVENUE SHARE BY REGION, 2019 (%)
  • FIGURE 65.MERCK: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 66.MERCK: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 67.MERCK: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 68.PFIZER: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 69.PFIZER: REVENUE SHARE, BY SEGMENT, 2019 (%)
  • FIGURE 70.PFIZER: REVENUE SHARE, BY REGION, 2019 (%)
  • FIGURE 71.TEVA: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 72.TEVA: REVENUE SHARE BY GEOGRAPHY, 2019 (%)
Back to Top